These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38756640)

  • 41. BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
    Li J; Wang Q; Ge J; Tian Y; Yao W
    Oncologist; 2021 Dec; 26(12):e2115-e2119. PubMed ID: 34516041
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report.
    Adachi Y; Yanagimura N; Suzuki C; Ootani S; Tanimoto A; Nishiyama A; Yamashita K; Ohtsubo K; Takeuchi S; Yano S
    BMC Cancer; 2020 Feb; 20(1):156. PubMed ID: 32093631
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness Treatment of a BRAF-ZKSCAN5 Fusion Gene Melanoma Case with Dabrafenib/Trametinib.
    Kato H; Kano S; Yasui Y; Nojiri Y; Yoshimitsu M; Nakamura M; Morita A
    Case Rep Oncol; 2023; 16(1):1007-1012. PubMed ID: 37900828
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gastrointestinal stromal tumors with BRAF gene fusions. A report of two cases showing low or absent KIT expression resulting in diagnostic pitfalls.
    Torrence D; Xie Z; Zhang L; Chi P; Antonescu CR
    Genes Chromosomes Cancer; 2021 Dec; 60(12):789-795. PubMed ID: 34398495
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The GIST of targeted therapy for malignant melanoma.
    Bello DM; Dematteo RP; Ariyan CE
    Ann Surg Oncol; 2014 Jun; 21(6):2059-67. PubMed ID: 24531699
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs?
    Senchak J; Ahr K; von Mehren M
    Curr Treat Options Oncol; 2022 May; 23(5):749-761. PubMed ID: 35349049
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characteristics of Real-World Patients with High-Risk
    Quaglino P; Ascierto PA; Consoli F; Queirolo P; Spagnolo F; Morelli MF; Berardi R; Chiarion-Sileni V; Tucci M; Troiani T; Melotti B; Rossi E; Mandala M; Rinaldi G; Marcon IG; Pizzuti M; Del Vecchio M
    Cancer Manag Res; 2023; 15():1271-1281. PubMed ID: 38027240
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dabrafenib and trametinib administration in patients with
    Shimoi T; Sunami K; Tahara M; Nishiwaki S; Tanaka S; Baba E; Kanai M; Kinoshita I; Shirota H; Hayashi H; Nishida N; Kubo T; Mamesaya N; Ando Y; Okita N; Shibata T; Nakamura K; Yamamoto N
    EClinicalMedicine; 2024 Mar; 69():102447. PubMed ID: 38333370
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Clinicopathological features and prognosis of 59 patients with platelet-derived growth factor α-mutant gastrointestinal stromal tumor].
    Sun XF; Gao XD; Yuan W; Sun JY; Fu M; Xue AW; Li H; Shu P; Fang Y; Hou YY; Shen KT; Sun YH; Qin J; Qin XY
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):880-887. PubMed ID: 32927513
    [No Abstract]   [Full Text] [Related]  

  • 51. Dabrafenib plus trametinib in patients with BRAF
    Subbiah V; Lassen U; Élez E; Italiano A; Curigliano G; Javle M; de Braud F; Prager GW; Greil R; Stein A; Fasolo A; Schellens JHM; Wen PY; Viele K; Boran AD; Gasal E; Burgess P; Ilankumaran P; Wainberg ZA
    Lancet Oncol; 2020 Sep; 21(9):1234-1243. PubMed ID: 32818466
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dabrafenib plus trametinib in patients with BRAF
    Davies MA; Saiag P; Robert C; Grob JJ; Flaherty KT; Arance A; Chiarion-Sileni V; Thomas L; Lesimple T; Mortier L; Moschos SJ; Hogg D; Márquez-Rodas I; Del Vecchio M; Lebbé C; Meyer N; Zhang Y; Huang Y; Mookerjee B; Long GV
    Lancet Oncol; 2017 Jul; 18(7):863-873. PubMed ID: 28592387
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Analysis of biological characteristics and prognosis on gastrointestinal stromal tumor with PDGFRA gene mutation].
    Qi C; Pan F; Li J; Li Y; Gao J; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1280-1284. PubMed ID: 30506540
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.
    Farag S; Somaiah N; Choi H; Heeres B; Wang WL; van Boven H; Nederlof P; Benjamin R; van der Graaf W; Grunhagen D; Boonstra PA; Reyners AK; Gelderblom H; Steeghs N
    Eur J Cancer; 2017 May; 76():76-83. PubMed ID: 28284172
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review.
    Fasano M; Della Corte CM; Caterino M; Pirozzi M; Rauso R; Troiani T; Martini G; Napolitano S; Morgillo F; Ciardiello F
    Front Med (Lausanne); 2021; 8():652005. PubMed ID: 35155453
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice.
    Rutkowski P; Ziętek M; Cybulska-Stopa B; Streb J; Głuszek S; Jankowski M; Łopacka-Szatan K; Las-Jankowska M; Hudziec P; Klimczak A; Olesiński T; Świtaj T; Koseła-Paterczyk H; Bylina E; Osuch C
    Eur J Surg Oncol; 2021 May; 47(5):1191-1195. PubMed ID: 32826113
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dabrafenib plus trametinib treatment for a patient with BRAF V600E-mutated large-cell lung carcinoma and a poor performance status.
    Nakajima Y; Nishijima Y; Niida A; Kiyama K; Sasaki A; Fujimoto Y; Ishizuka A; Ehara J; Ogita S; Norisue Y
    Int Cancer Conf J; 2022 Oct; 11(4):266-269. PubMed ID: 36186221
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Strategic Exploration of Targeted Therapy for BRAF Non-V600E Mutant Lung Cancer].
    Zhang H; Gao J; Guo W; Yu B; Yang H; Liu Y
    Zhongguo Fei Ai Za Zhi; 2022 Feb; 25(2):86-91. PubMed ID: 35224961
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
    Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski CC; Cabanillas ME; Boran A; Ilankumaran P; Burgess P; Romero Salas T; Keam B
    Ann Oncol; 2022 Apr; 33(4):406-415. PubMed ID: 35026411
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor.
    Bauer S; George S; von Mehren M; Heinrich MC
    Front Oncol; 2021; 11():672500. PubMed ID: 34322383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.